Prof. Li graduated from the Faculty of Medicine at the University of Hong Kong in 2004. He completed his basic and higher physician training in the Department of Medicine at Queen Mary Hospital. In 2012, after completing specialist training in both Advanced Internal Medicine and Palliative Medicine, he was admitted as a fellow of internal medicine. Subsequently, Prof. Li worked as a resident specialist and associate consultant in the Palliative Medical Unit at Grantham Hospital. During this time, he also served as an honorary clinical assistant professor in the Medical Ethics and Humanities Unit, where he was involved in teaching and tutoring medical students.

Starting in 2018, Prof. Li underwent specialist training in Medical Oncology at Queen Mary Hospital and was accredited as a specialist in Medical Oncology in 2020. He is currently a Clinical Assistant Professor at the Centre of Cancer Medicine, Department of Medicine, and Department of Obstetrics and Gynaecology at the School of Clinical Medicine, the University of Hong Kong. Prof. Li focuses on the treatment of genitourinary and gynecological cancers. His research interests include clinical trials and translational research on novel cancer therapeutics. Additionally, he is involved in teaching cancer medicine to undergraduates at the medical school.

Prof. Li is also a member of various professional bodies, including the Medical Oncology Specialty Board of the Hong Kong College of Physicians (HKCP), and the Hong Kong Society of Geriatrics Oncology.

1. Li BC, Chiu J, Shing K, Kwok GG, Tang V, Leung R, Ma KW, She WH, Tsang J, Chan A, Cheung TT. The Outcomes of Systemic Treatment in Recurrent Hepatocellular Carcinomas Following Liver Transplants. Advances in Therapy. 2021 Jun 1:1-1. [Citation: - ] [IF: 3.85 (JCR 2020)]
2. Wong CY, Leung R, Kwok GW, Tsang J, Li B, Yau T, Chiu J. Safety and tolerability of subcutaneous trastuzumab and intravenous pertuzumab as adjuvant treatment for HER2 positive breast cancer Postgrad Med J. 2021 May 26. doi:10.1136/postgradmedj-2021-140319 [Citation: -] [IF: 2.40 (JCR 2020)]
3. Wong JS, Dong Y, Tang V, Leung T, Yeung CSY, Tai A, Law A, Shum T, Kwok GG, Li BC, Leung R, Chiu J, Ma KW, She WH, Tsang J, Cheung TT, Yau T The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong—A Territory-Wide Cohort Study Cancers (Basel). 2021 Apr 21;13(9):2002. [Citation: - ] [IF: 6.64 (JCR 2020)]
4. Dong Y, Wong JSL, Sugimura R, Lam KO, Li B, Kwok GGW, Leung R, Chiu JWY, Cheung TT, Yau T Recent Advances and Future Prospects in Immune Checkpoint (ICI)-Based Combination Therapy for Advanced HCC. Cancers (Basel). 2021 Apr 18;13(8):1949. [Citation: - ] [IF: 6.64 (JCR 2020)]
5. Tsang J, Wong JSL, Kwok GGW, Li BCW, Leung R, Chiu J, Cheung TT, Yau T. Drug Profile: Nivolumab plus Ipilimumab for Patients with Hepatocellular Carcinoma previously treated with Sorafenib Expert Review of Gastroenterology & Hepatology 2021 Mar 5 [Citation: 2 ] [IF: 3.87 (JCR 2020)]